Lv1
84 积分 2024-01-19 加入
The cGAS–STING pathway as a therapeutic target in inflammatory diseases
7天前
已完结
Tryptophan Oxidation of a Monoclonal Antibody Under Diverse Oxidative Stress Conditions: Distinct Oxidative Pathways Favor Specific Tryptophan Residues
1个月前
已完结
Investigation of monoclonal antibody fragmentation artifacts in non-reducing SDS-PAGE
2个月前
已完结
Reversing resistance to cancer immune therapy with antibodies that target GDF-15 protein
2个月前
已完结
IFNAR1 and IFNAR2 polymorphisms confer susceptibility to multiple sclerosis but not to interferon-beta treatment response
2个月前
已完结
First soluble TCR therapy opens ‘new universe’ of cancer targets
3个月前
已完结
What matters most in commercial success: first-in-class or best-in-class?
3个月前
已完结
First-in-class versus best-in-class: an update for new market dynamics
3个月前
已完结
Impact of a five-dimensional framework on R&D productivity at AstraZeneca
3个月前
已完结
Anti–Glypican 3 Antibody as a Potential Antitumor Agent for Human Liver Cancer
4个月前
已完结
皖公网安备34019202002308
